Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Wan-Jen Hong, MD
Prelude Therapeutics
N/A
Poster(s):
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
